Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 8:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 29,139 matching trials from the live ClinicalTrials.gov search.
Conditions
Gastrointestinal Stromal Tumor
Interventions
Ganetespib
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Portland, Oregon + 1 more
Recruiting Phase 4 Interventional Accepts healthy volunteers

Optimization of Pediatric Tonsillectomy to IMprove AnaLgesia

NCT06576830
Conditions
Pain, Postoperative, Tonsillar Hypertrophy, Tonsillitis, Pediatric Sleep Apnea, Sleep-Disordered Breathing
Interventions
Methadone, Fentanyl/Hydromorphone
Drug
Lead sponsor
Duke University
Other
Eligibility
3 Years to 17 Years
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults

NCT05089630
Conditions
Cytomegalovirus Infections
Interventions
Pentamer (low)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(med)/Adjuvant vaccine, Pentamer (high)/gB(med)/Adjuvant vaccine, Placebo (saline solution)
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
18
States / cities
Anaheim, California • Long Beach, California • Los Angeles, California + 15 more
Conditions
Prostate Cancer
Interventions
Pazopanib, Docetaxel, Prednisone, Pegfilgrastim
Drug
Lead sponsor
Daniel George, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Chicago, Illinois • Durham, North Carolina
Terminated Phase 2 Interventional Results available

A Phase II Trial of Poly-ICLC for Low-Grade Gliomas

NCT04544007
Conditions
NF1, Low-grade Glioma
Interventions
Poly ICLC
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Up to 22 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 7 more
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
AUY922, Bortezomib, Dexamethasone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Scottsdale, Arizona • San Antonio, Texas
Conditions
Malignant Glioma of Brain
Interventions
Acetazolamide, Temozolomide
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of the Fluoride Dose Response Using In Situ Caries Model

NCT04763044
Conditions
Caries
Interventions
0 ppm F, 250 ppm F as MFP, 1100 ppm as MFP, 2800 ppm F as MFP, 1100 ppm SnF2
Drug
Lead sponsor
Procter and Gamble
Industry
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Chronic Lymphocytic Leukemia
Interventions
MDX-1342
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
Boston, Massachusetts • Buffalo, New York • Houston, Texas
Conditions
AMN, AMN Gene Mutation, X-ALD
Interventions
SBT101 Treatment
Genetic
Lead sponsor
SwanBio Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Scar, Cesarean Section; Dehiscence
Interventions
Scar Deactivation Surface Release Technique protocol, Scar Infiltration with 0.25-1% Lidocaine, Physical therapy
Other
Lead sponsor
Jennifer Loomis
Federal
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Scott Air Force Base, Illinois
Completed Phase 1Phase 2 Interventional Results available

Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients

NCT00469209
Conditions
Myeloma
Interventions
Trisenox (Arsenic Trioxide), Velcade (Bortezomib), Melphalan, Vitamin C (Ascorbic Acid)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 1Phase 2 Interventional Results available

BIO 300 Non-Small Cell Lung Cancer Study

NCT02567799
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
BIO 300 Oral Suspension, Paclitaxel, Carboplatin, Radiotherapy
Drug · Radiation
Lead sponsor
Humanetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
4
States / cities
Baltimore, Maryland • Detroit, Michigan • Milwaukee, Wisconsin
Conditions
Lung Cancer
Interventions
Single-fraction stereotactic body radiation therapy (SBRT), Multiple-fraction stereotactic body radiation therapy (SBRT)
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
35
States / cities
Auburn, California • Berkeley, California • Cameron Park, California + 30 more
Conditions
Sialorrhea
Interventions
Incobotulinum Toxin A, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Solid Tumor, Advanced Cancer, Metastatic Solid Tumor
Interventions
DS-1055a
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
New York, New York • Cincinnati, Ohio
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Diltiazem Administration on CP-945,598 Pharmacokinetics

NCT00645463
Conditions
Obesity
Interventions
CP-945,598
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Soft Tissue Sarcoma, Bone Sarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Bone Sarcoma, Metastatic Soft-tissue Sarcoma, Unresectable Bone Sarcoma
Interventions
Ascorbate, Gemcitabine
Drug
Lead sponsor
David Dickens
Other
Eligibility
13 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Meningococcal Infections
Interventions
MenACWY-CRM, Licensed meningococcal ACWY vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
2 Years to 10 Years
Enrollment
2,907 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
52
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Downey, California + 39 more
Conditions
Cystic Fibrosis
Interventions
Mesenchymal Stem Cells
Biological
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Advanced Cancers
Interventions
Fentanyl Buccal Tablet, Placebo Buccal Tablet, Questionnaires
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 4 Interventional Results available

B/F/TAF Switch Study for HIV-HBV Coinfection

NCT03797014
Conditions
HIV-1-infection, Hepatitis B
Interventions
B/F/TAF
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Conditions
Schizophrenia
Interventions
AMG 747, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Anaheim, California • Cerritos, California • Culver City, California + 15 more
Conditions
Hemophilia B
Interventions
rFIXFc
Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Chicago, Illinois • Indianapolis, Indiana • Boston, Massachusetts + 3 more